Data management for heterogeneous genomic datasets

Next Generation Sequencing (NGS), a family of technologies for reading the DNA and RNA, is changing biological research, and will soon change medical practice, by quickly providing sequencing data and high-level features of numerous individual genomes in different biological and clinical conditions. Availability of millions of whole genome sequences may soon become the biggest and most important ”big data” problem of mankind. In this exciting framework, we recently proposed a new paradigm to raise the level of abstraction in NGS data management, by introducing a GenoMetric Query Language (GMQL) and demonstrating its usefulness through several biological query examples. Leveraging on that effort, here we motivate and formalize GMQL operations, especially focusing on the most characteristic and domain-specific ones. Furthermore, we address their efficient implementation and illustrate the architecture of the new software system that we have developed for their execution on big genomic data in a cloud computing environment, providing the evaluation of its performance. The new system implementation is available for download at the GMQL website (http://www.bioinformatics.deib.polimi.it/GMQL/); GMQL can also be tested through a set of predefined queries on ENCODE and Roadmap Epigenomics data at http://www.bioinformatics.deib.polimi.it/GMQL/queries/

Framework for Supporting Genomic Operations

Next Generation Sequencing (NGS) is a family of technologies for reading the DNA or RNA, capable of producing whole genome sequences at an impressive speed, and causing a revolution of both biological research and medical practice. In this exciting scenario, while a huge number of specialized bio-informatics programs extract information from sequences, there is an increasing need for a new generation of systems and frameworks capable of integrating such information, providing holistic answers to the needs of biologists and clinicians. To respond to this need, we developed GMQL, a new query language for genomic data management that operates on heterogeneous genomic datasets. In this paper, we focus on three domain-specific operations of GMQL used for the efficient processing of operations on genomic regions, and we describe their efficient implementation; the paper develops a theory of binning strategies as a generic approach to parallel execution of genomic operations, and then describes how binning is embedded into two efficient implementations of the operations using Flink and Spark, two emerging frameworks for data management on the cloud

Big Data Transforms Discovery-Utilization Therapeutics Continuum.

Enabling omic technologies adopt a holistic view to produce unprecedented insights into the molecular underpinnings of health and disease, in part, by generating massive high-dimensional biological data. Leveraging these systems-level insights as an engine driving the healthcare evolution is maximized through integration with medical, demographic, and environmental datasets from individuals to populations. Big data analytics has accordingly emerged to add value to the technical aspects of storage, transfer, and analysis required for merging vast arrays of omic-, clinical-, and eco-datasets. In turn, this new field at the interface of biology, medicine, and information science is systematically transforming modern therapeutics across discovery, development, regulation, and utilization

Combined population dynamics and entropy modelling supports patient stratification in chronic myeloid leukemia

Modelling the parameters of multistep carcinogenesis is key for a better understanding of cancer progression, biomarker identification and the design of individualized therapies. Using chronic myeloid leukemia (CML) as a paradigm for hierarchical disease evolution we show that combined population dynamic modelling and CML patient biopsy genomic analysis enables patient stratification at unprecedented resolution. Linking CD34+ similarity as a disease progression marker to patientderived gene expression entropy separated established CML progression stages and uncovered additional heterogeneity within disease stages. Importantly, our patient data informed model enables quantitative approximation of individual patients’ disease history within chronic phase (CP) and significantly separates “early” from “late” CP. Our findings provide a novel rationale for personalized and genome-informed disease progression risk assessment that is independent and complementary to conventional measures of CML disease burden and prognosis

A Path to Implement Precision Child Health Cardiovascular Medicine.

Congenital heart defects (CHDs) affect approximately 1% of live births and are a major source of childhood morbidity and mortality even in countries with advanced healthcare systems. Along with phenotypic heterogeneity, the underlying etiology of CHDs is multifactorial, involving genetic, epigenetic, and/or environmental contributors. Clear dissection of the underlying mechanism is a powerful step to establish individualized therapies. However, the majority of CHDs are yet to be clearly diagnosed for the underlying genetic and environmental factors, and even less with effective therapies. Although the survival rate for CHDs is steadily improving, there is still a significant unmet need for refining diagnostic precision and establishing targeted therapies to optimize life quality and to minimize future complications. In particular, proper identification of disease associated genetic variants in humans has been challenging, and this greatly impedes our ability to delineate gene-environment interactions that contribute to the pathogenesis of CHDs. Implementing a systematic multileveled approach can establish a continuum from phenotypic characterization in the clinic to molecular dissection using combined next-generation sequencing platforms and validation studies in suitable models at the bench. Key elements necessary to advance the field are: first, proper delineation of the phenotypic spectrum of CHDs; second, defining the molecular genotype/phenotype by combining whole-exome sequencing and transcriptome analysis; third, integration of phenotypic, genotypic, and molecular datasets to identify molecular network contributing to CHDs; fourth, generation of relevant disease models and multileveled experimental investigations. In order to achieve all these goals, access to high-quality biological specimens from well-defined patient cohorts is a crucial step. Therefore, establishing a CHD BioCore is an essential infrastructure and a critical step on the path toward precision child health cardiovascular medicine